LOGIN  |  REGISTER
C4 Therapeutics

InMode (NASDAQ: INMD) Stock Quote

Last Trade: US$18.24 0.32 1.79
Volume: 436,040
5-Day Change: 1.67%
YTD Change: -17.99%
Market Cap: US$1.390B

Latest News From InMode

YOKNEAM, Israel , Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024 . Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of... Read More
IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd . (Nasdaq: INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California in a lawsuit filed against sellers identified to be the source of unlawful counterfeit sales of Morpheus8 radiofrequency devices and cartridge accessories. On September 3, 2024 , the... Read More
Expects Q3 Revenue Between $130.0 Million - $130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million - $420 Million Conference call to be held on Wednesday, October 30, 2024 , at 8:30 a.m. Eastern Time YOKNEAM, Israel , Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies,... Read More
YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani , President of North America effective September 30, 2024 . His departure follows that of Dr. Spero Theodorou , Chief Medical Officer, and Dan Wilson , VP of Sales USA . In addition to the departure of the three executives from InMode's North... Read More
YOKNEAM, Israel , Sept. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced that its Board of Directors has approved a share repurchase program of up to 7.68 million ordinary shares. "Following the completion of our share buyback program announced earlier this year, the board's authorization to enact this new share repurchase program demonstrates... Read More
YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca , Chief Financial Officer will present in-person at the 2024 Baird Global Healthcare Conference in New York on Sept. 10, 2024 . The fireside chat, moderated by Jeff Johnson , Senior Research Analyst, is scheduled for 2:00 pm Eastern Time on Tuesday , Sept.... Read More
YOKNEAM, Israel , Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9 th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy , Chief Executive Officer and Yair Malca , Chief Financial Officer Format: Virtual one-on-one meetings When:... Read More
YOKNEAM, Israel , Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024 . Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million , a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology... Read More
HealthStocksHub
IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is pleased to announce the introduction of IgniteRF, a ground-breaking minimally invasive workstation inclusive of nine technologies which offer soft tissue contraction across multiple tissue... Read More
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI , July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here . The... Read More
IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, is pleased to announce an additional FDA 510(k) clearance for the Morpheus8 technology. Morpheus8 is the first and only fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The U.S. Food and Drug Administration (FDA) has cleared the use of the... Read More
Expects Q2 Revenue Between $86.2M - $86.3M , Pro-Forma Revenue (including new platform pre-orders) Between $102.4M - $102.5M , Decreases FY 2024 Guidance to $430M - $440M Conference call to be held on Thursday, Aug. 1, 2024 , at 8:30 a.m. Eastern Time YOKNEAM, Israel , July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, announced today that it expects to... Read More
YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024 . The fireside chat, moderated by Matt Taylor , Managing Director, Senior Healthcare Analyst, is... Read More
HealthStocksHub
IRVINE, Calif. , May 8, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with P1 Offshore Racing and sponsor the only female driver, Victoria Rand , as part of Class 1. This partnership signifies a historic step... Read More
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel , May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: Quarterly GAAP revenue of... Read More
YOKNEAM, Israel , April 15, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the United States District Court... Read More
Expects Q1 Revenue Between $80.0M - $80.1M , Pro Forma Revenue (including new platform pre-orders) Between $95.7M - $95.8M , Decreases FY 2024 Guidance to $485M - $495M Conference call to be held on Thursday, May 2, 2024 , at 8:30 a.m. Eastern Time YOKNEAM, Israel , April 9, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to... Read More
YOKNEAM, Israel , April 3, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in April and May: 23rd Annual Needham Virtual Healthcare Conference Presenters: Moshe Mizrahy , Chief Executive Officer and Chairman, Yair Malca , Chief Financial Officer and Spero Theodorou , Chief Medical... Read More
YOKNEAM, Israel , March 4, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq : INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in March: Oppenheimer 34th Annual Healthcare MedTech & Services Conference Presenters: Moshe Mizrahy , Chief Executive Officer and Chairman Format: Virtual fireside chat moderated by Suraj Kalia , Managing... Read More
YOKNEAM, Israel , Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023 . Fourth Quarter 2023 Highlights: Quarterly revenue of $126.8 million , compared to $133.6 in the fourth quarter of 2022. Quarterly revenues from consumables and... Read More
Conference call to be held on Tuesday, February 13, 2024 , at 8:30 a.m. Eastern Time YOKNEAM, Israel , Jan. 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2023 before the Nasdaq market opens on Tuesday, February 13, 2024. InMode is currently finalizing its... Read More
YOKNEAM, Israel , Dec. 6, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it is revising its full-year 2023 guidance. According to management, this revision is primarily due to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales, mainly in North America . Based on current... Read More
YOKNEAM, Israel , Nov. 6, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in November and December: Jefferies London Healthcare Conference Presenters: Moshe Mizrahy , Chief Executive Officer and Chairman Format: In-person fireside chat moderated by Matt Taylor , Senior Equity... Read More
YOKNEAM, Israel , Nov. 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2023 . Third Quarter 2023 Highlights: Quarterly revenue of $123.1 million , an in crease of 2 % compared to the third quarter of 2022. InMode's proprietary surgical technology platforms... Read More
YOKNEAM, Israel , Oct. 13, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, announced that it filed a patent infringement complaint in the United States District Court for the Central District of California alleging that BTL Industries' UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe U.S. Patent No.... Read More
Conference call to be held on Thursday, Nov. 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel , Oct. 12, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2023 before the Nasdaq market opens on Thursday, Nov. 2, 2023. InMode is currently finalizing its financial results for... Read More
YOKNEAM, Israel , Oct. 9, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, addressed today the status of the Company's activity in Israel. Moshe Mizrahy , InMode's Chairman and Chief Executive Officer said: "InMode is committed to supporting all customers, distributors, employees, and salespeople worldwide. We prioritize the safety and well-being of our employees... Read More
YOKNEAM, Israel , Sept. 5, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in September: Baird Healthcare Conference Presenters: Yair Malca , Chief Financial Officer and Dr. Spero Theodorou , Chief Medical Officer Format: In-person fireside chat moderated by Jeff Johnson , Senior... Read More
YOKNEAM, Israel , Sept. 5, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in September: Baird Healthcare Conference Presenters: Yair Malca , Chief Financial Officer and Dr. Spero Theodorou , Chief Medical Officer Format: In-person fireside chat moderated by Jeff Johnson , Senior... Read More
YOKNEAM, Israel , Aug. 1, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events in August: Canaccord Genuity's 43 rd Annual Growth Conference Presenters: Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer Format: In-person fireside chat... Read More
YOKNEAM, Israel , July 27, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2023 . Second Quarter 2023 Highlights: Record quarterly revenue of $136.1 million , an increase of 20% compared to the second quarter of 2022. InMode's proprietary surgical technology... Read More
YOKNEAM, Israel , July 25, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) (" InMode "), a leading global provider of innovative medical technologies, is pleased to announce the completion of a significant intellectual property (IP) transaction in the women's health and wellness market. InMode has acquired all the intellectual property assets of Viveve Medical Inc. Viveve is a medical technology company focused on women's... Read More
Conference call to be held on Thursday, July 27, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel , July 12, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2023 before the Nasdaq market opens on Thursday, July 27, 2023 . InMode is currently finalizing its financial results... Read More
YOKNEAM, Israel , May 17, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events: BNPP Exane Aesthetics Day Presenters: Moshe Mizrahy , Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer Format: Virtual fireside chat... Read More
YOKNEAM, Israel, May 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2023 . First Quarter 2023 Highlights: Quarterly revenue of $106.1 million , an increase of 23.5% compared to the first quarter of 2022. InMode's proprietary surgical technology platforms... Read More
Conference call to be held on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel , April 12, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2023 before the Nasdaq market opens on Tuesday, May 2, 2023. InMode is currently finalizing its financial results for... Read More
YOKNEAM, Israel , March 13, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that that it does not hold cash deposits or securities at Silicon Valley Bank. The company maintains its cash and non-insured deposits at U.S. money center banks and large Israeli financial institutions. As a result, the company does not expect the closure of Silicon... Read More
YOKNEAM, Israel , March 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced that Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Barclays Global Health Conference in Miami on March 15, 2023 . The fireside chat, moderated by Matt Miksic , equity research analyst, is scheduled for... Read More
YOKNEAM, Israel, Feb. 14, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2022 . Fourth Quarter 2022 Highlights: Record quarterly revenue of $133.6 million , an increase of 21% compared to the fourth quarter of 2021. InMode's proprietary surgical... Read More
Conference call to be held on Tuesday, February 14, 2023 , at 8:30 a.m. Eastern Time YOKNEAM, Israel , Jan. 11, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD ) , a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2022 before the Nasdaq market opens on Tuesday, February 14, 2023. InMode is currently finalizing its... Read More
YOKNEAM, Israel , Jan. 3, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy , Chairman and Chief Executive Officer, Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present virtually at the 25 th Annual Needham Growth Conference on Jan. 12, 2023 . The fireside chat, moderated by Mike Matson... Read More
IRVINE, Calif. , Nov. 25, 2022 /CNW/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is proud to announce the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation. MGD is a major cause... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB